Oct 19, 2026 · 5 min
AI rebound, tariff gains and a biotech trial collapse reshape stocks
CoreWeave Rises, Cleveland Cliffs Gains, EyePoint Sinks to Record Low After Drug Trial Fails
The episode shows how analyst sentiment, trade policy, earnings and clinical evidence can rapidly reprice very different companies.
- 1CoreWeave rebounds as Goldman Sachs upgrades the stock and strength returns to AI-related shares.
- 2Cleveland-Cliffs rallies after earnings quadruple year over year amid higher steel prices and metal tariffs.
- 3EyePoint suffers a record plunge after its wet AMD treatment fails a Phase 3 trial.
Don't miss
EyePoint falls to a record low after its wet AMD treatment fails a Phase 3 trial.
The brief
CoreWeave rebounds after a sharp weekly decline, helped by renewed strength across AI-related shares and an upgrade from Goldman Sachs.
Cleveland-Cliffs rallies as earnings quadruple year over year, with higher steel prices and the effects of a 50% metal tariff supporting the result.
EyePoint delivers the episode’s sharpest reversal: its shares plunge to a record low after a late-stage wet AMD treatment fails its Phase 3 trial.
The closing preview shifts from daily market moves to long-term urban planning, asking how innovation and artificial intelligence can help cities manage rapid growth.
Together, the stories show how quickly markets respond when expectations change—through an analyst upgrade, policy-driven pricing power or decisive clinical evidence.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.